Scancell Share Discussion Threads

[inanaco] 17/4/2024 18:03

thats revenue to the company scancell .... NOT sales

Modi – 1 and
Modi – 2 could potentially deliver $3bn in peak annual revenues, if all goes well.

£8 lol

[inanaco] 17/4/2024 17:20

google

Vimentin is highly expressed in primary and metastatic tumors derived from epithelial tissues, which normally express keratin intermediate filaments. Vimentin expression in tumor tissue correlates with increased metastatic potential

What is vimentin expression in squamous cell carcinoma?

All cases were classified according to the histological malignancy grading system proposed by Anneroth. All of the carcinomas were found to express cytokeratin, while 60.4% expressed vimentin. Vimentin was particularly noted in all tumors scored to have highly malignant cells.


Vimentin is considered a hallmark of the epithelial-mesenchymal transition in epithelial cells [8,9]. Increased vimentin expression has previously been associated with tumor progression and metastasis in many human cancers [10,11].1 Mar 2020


Modi1 contains 2 vimentin peptides

cytokeratin

Modi-2

Scancell
› modi-2
Cytokeratin expression, along with the cytoskeletal protein vimentin, results in increased invasion and metastasis in breast cell carcinomas and melanomas. BiP ...

[inanaco] 17/4/2024 16:50

modi1 or its component's could be used in 17 different cancers so you could call it universal

JohnnyB1

Posts: 409

Price: 9.55

No Opinion

RE: Modi 1Today 15:04
Just looking at the link to Lindy’s talk at the Immuno-Oncology Summit, Lindy makes reference to a "universal cancer vaccine". Maybe I am mistaken but I have not heard her refer to a "universal cancer vaccine" previously :-

hxxps://www.immuno-oncologyeurope.com/cancer-vaccines#RobertMeehan

"SCIB1 a DC targeting DNA vaccine gives at impressive 85% response rate in combination with ipilimumab and nivolumab in advanced melanoma. Citrullination occurs in stressed tumor cells and makes an excellent target for a universal cancer vaccine. Modi-1 targeting citrullination is currently in phase II clinical trial."

[inanaco] 17/4/2024 16:25

so if i invested my Scancell holdings I would get £1000 dividend ....

a building society would beat that chap ....

[inanaco] 17/4/2024 16:19

Dividend per Share 0.20p or £0.002

is that another get rich quick scheme ?

[inanaco] 17/4/2024 16:14

Ivy what was the dividend per share ?

[inanaco] 17/4/2024 16:00

LOL

I reposted your nonsense from the other day ....

i didn't respond to it at the time

but you seem to be back advising again ...

by the way Lindy counted the chickens ......... at 90% expectation

I can run with those odds .. oh i did i filled my ISA again

[inanaco] 17/4/2024 15:39

now Ivy you can't tell me i was wrong when i said at 30p its over valued ....

look in my history

[inanaco] 17/4/2024 15:25

what scancell has told us .......

The SCOPE trial has now successfully transitioned into the second stage, which will recruit a further 27 patients (for a total of 43). The aim is to achieve at least 18 further responses (i.e., 27 responses in total) which would statistically demonstrate that SCIB1, in combination with doublet therapy, exceeds currently achievable ORRs. Recruitment is on track with data available in H1 2024. Based upon the first 13 patients there is a greater than 90% probability that the second phase will also be successful.

H1 2024

we are in Qtr 2

[ivyspivey] 17/4/2024 15:22

Nigel agree completely.
The only thing that matters to 99% of folk invested here or elsewhere is the share price as you can’t buck the market.
You can never count your chickens Nana bit if the share price is higher here than HVO by end of June I will be a happy bunny.

[inanaco] 17/4/2024 15:09

Crumbs advised us he is using his skillset learnt from studying scancell to move into better things

what i would say those demanding more information from Scancell would appear to be far more stressed about holding than me ...

but what do i know .... Ivy holds HVO at 18 times earnings

Barclays 7 times earnings

Rolls Royce 14 times earnings

I thought it expensive ... hey the AIM market knows what its doing

for 10 years we have watched wave after wave of Val shareholders go broke

you can't beat experience

[inanaco] 17/4/2024 14:47

Nigel not really ... always stated SCIB1 was good enough alone for the investment

which is why its a no risk strategy for me ... plus i have a far more diverse portfolio than most here, after all I do live well off dividend income

having seen the share as low as 3.5p sitting here at 10p will not change my outlook

bermuda reduced his investment here on moditope news so is not exposed with Crumbs who Bought MKA

ATB

[nigelpm] 17/4/2024 13:46

Spot on Bermuda - Inanaco is guilty of having very bullish views and always looking on the positive side - that's not surprising when you have (as publicly stated) a huge amount riding on the outcome - c. £150k.

A high risk strategy that could easily go wrong.

[bermudashorts] 17/4/2024 13:35

inanaco,

It's not worth discussing this further. On several occasions Scancell has released data for SCIB1 even though it has yet to meet the 70% threshold so the argument that they need to wait for the endpoints to be met for Modi1 don't hold fire. We have seen updates for just one or two patients for both products and updates with only safety data, it doesn't have to be efficacy - anything would be nice!

However you want to explain it away, it's disappointing to me that we have heard nothing about the combination and neoadjuvant arms of the Modi1 trial. Looking at the wider picture, I'm also disappointed that this trial has been running for over 2 years now and so far has not produced the frequent updates we were told to expect.

Hopefully the news flow will improve starting with the forthcoming presentation. I hope you're right and that it does included updated monotherapy results.

[inanaco] 17/4/2024 13:04

Octupus :lindy is not talking about good t cell generated from the vaccine but "good t cell Reponses" because of the vaccine

so it is a material change hopefully prompting an RNS update if they are using current data known


"I am also looking forward to presenting early data from patients receiving Modi-1 as a monotherapy in range of hard-to-treat solid tumours, which has shown good T cell responses, safety and tolerability. Following on from AACR, there has been significant interest in the clinical development of therapeutic cancer vaccines, and I am excited to demonstrate the progress Scancell has made in this class of immunotherapies."

[octopus100] 17/4/2024 12:43

Its great that they are making presentations however unless they are presenting new data, which it isn't obvious they are - what is the point of releasing an RNS?
I guess on the plus side they wouldn't be presenting data if there were any negative developments.

[inanaco] 17/4/2024 12:34

CheckMate 214
nivolumab + ipilimumab vs. sunitinib
phase 3 550 vs. 446 Untreated, advanced or metastatic renal cell carcinoma with clear cell composition,

performance status of ≥70% PFS (median): 12.3 months vs. 12.3 months)

OS (median): 55.7 months vs. 38.4 months

ORR(median): 39.3% vs. 32.4%

[inanaco] 17/4/2024 12:22

Yes Roger one in the eye for Biontech and Moderna

[inanaco] 17/4/2024 12:21

Modi1 in Renal

7. Conclusions
Despite the clinical success of current anti-CTLA-4, anti-PD-1/PD-L1 agents, a significant number of RCC patients remain unresponsive or even develop resistance. In such a complicated tumor immune environment, blocking a single checkpoint may result in the activation of other immune modulators. Targeting novel ICIs (LAG-3, TIM-3, and TIGIT) and B7-family ligands alone or in association with first-series ICIs may be future promising approaches for RCC treatment. In addition, further preclinical or clinical studies need to assess the validity and applicability of prognostic biomarkers, which might help to personalize checkpoint combination therapy and ultimately increase the clinical response rate.

[rogerbridge] 17/4/2024 12:19

An interesting comment by Lindy "off the shelf,"

[inanaco] 17/4/2024 12:01

Bermuda

Scancell expects the initial topline data readout from this double checkpoint arm of the study in Q4 2023.

they clearly felt a read out at 15 patients gave the green light for 43 patients

indeed they even calculated probability of success at 90%